SecBot SecBot
EFFECT ·Filed Nov 13, 2026

FATE

FATE THERAPEUTICS INC
BEARISH
Impact 5/10
Horizonweeks Processed4d ago SEC9999999995-26-003536
IPO/offering going effective
Actionable Insight ▼ Bearish

Monitor for takedowns under the ATM facility or any follow-on offering, which would crystallize dilution. The company's cash runway and pipeline milestones will determine the pace of capital deployment.

DirectionBearish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+1
Entry
$1.28
T+0 close · Nov 13, 2026 · via day close
Latest settled
−10.94%
T+1 · $1.14
Vs SPY
−9.03%
α at T+1
Next horizon
T+5
in 3d
  1. T+0 · Nov 13 $1.28entry
  2. T+1 · 18h ago −10.94%α −9.03% · $1.14
  3. T+5 · in 3d Pending
  4. T+20 · in 27d Pending
  5. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Fate Therapeutics' universal shelf registration (S-3, File No. 333-299862) became effective on November 12, 2026, enabling the company to sell up to $300M in securities including a $100M ATM facility. As a pre-revenue clinical-stage biotech with $139.1M cash and ongoing net losses, this effectiveness signals potential near-term dilution to fund pipeline development.

Key Facts

  • Shelf registration (File No. 333-299862) became effective on November 12, 2026
  • Shelf registers up to $300M in securities including a $100M ATM facility with Leerink Partners
  • Company had $139.1M cash as of September 30, 2026
  • Pre-revenue clinical-stage biotech with Q3 2026 net loss of $0.25 per share
  • Normal daily move for FATE is 5.8% (30-day volatility)

Financial Impact

Up to $300M in potential dilution; $100M ATM facility can be drawn at any time

dilutioncash position

Risk Factors

  • Immediate dilution risk if company draws on ATM facility or conducts a follow-on offering
  • Pre-revenue status with ongoing net losses increases dependence on capital markets
  • Shelf effectiveness removes regulatory barrier to rapid equity issuance

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
EFFECT Filing (Primary)9999999995-26-003536
Document: 9999999995-26-003536-index.html9999999995-26-003536
Document: 9999999995-26-003536.txt9999999995-26-003536

Track record

21 reports on FATE

Performance horizon

4 of 8 bullish or bearish reports moved the stock their way by T+5. Best: +30.25% at T+5 after the Nov 5, 2026 report. 8 of 9 went positive at some point.

Filters
  1. Nov 13, 20264d ago EFFECT Bearish 5/10 Viewing Entry $1.28 Now $1.14 +10.94% settles Nov 20
  2. Nov 12, 20264d ago 424B5 Bearish 4/10 Entry $1.28 Now $1.14 +10.94% settles Nov 20
  3. Nov 9, 20267d ago SC 13D/A Neutral 2/10 Entry $1.77 Now $1.14 −35.59% settles Nov 17
  4. Nov 5, 202611d ago S-3 Neutral 3/10 Entry $1.84 to $1.28 Now $1.14 −37.87% ▼ −30.25% −32.84% vs SPY
  5. Nov 5, 202611d ago 424B5 Bearish 5/10 Entry $1.84 to $1.28 Now $1.14 +37.87% ▲ +30.25% +32.84% vs SPY
  6. Nov 5, 202611d ago 8-K Bearish 5/10 Entry $1.84 to $1.28 Now $1.14 +37.87% ▲ +30.25% +32.84% vs SPY
  7. Nov 5, 202611d ago 8-K Neutral 4/10 No price data
  8. Nov 5, 202611d ago Press Release Neutral 4/10 Entry $1.85 to $1.34 Now $1.14 −38.38% ▼ −27.57% −30.86% vs SPY
  9. Nov 4, 202612d ago Institutional Cluster Neutral 3/10 Entry $2.09 to $1.61 Now $1.14 −45.45% ▼ −23.21% −22.29% vs SPY
  10. Nov 3, 202613d ago 144 Neutral 2/10 Entry $2.04 to $1.77 Now $1.14 −44.12% ▼ −13.24% −12.65% vs SPY
Showing 10 of 21

US Market Status

Market Closed · Opens in 8h 19m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 13, 2026